NanoKnife Cancer Treatment in China: IRE, Evidence & Hospitals
NanoKnife is the trade name commonly used for irreversible electroporation (IRE), a non-thermal local-ablation technique. China has hospitals with documented IRE experience, but the useful question is whether local ablation fits the exact cancer, stage, anatomy and previous treatment.
Quick answer: IRE can be a legitimate local-treatment question for selected tumors. For pancreatic cancer, expert consensus describes selected use in stage III or inoperable recurrent disease, while comparative evidence does not establish IRE as universally superior to alternatives such as SABR. Provider capability must be separated from patient eligibility and treatment effectiveness.
✓ IRE is local treatment, not systemic therapy
✓ Independent evidence separated from provider claims
✓ No universal success-rate or cure claim
✓ Current cost requires a case-specific quote
What Is NanoKnife / Irreversible Electroporation?
IRE places electrode probes in or around a target and delivers short high-voltage electrical pulses. The intended ablation mechanism is electrical rather than thermal.
Non-thermal electrical ablation
IRE creates irreversible membrane disruption in targeted cells. Unlike radiofrequency or microwave ablation, heating is not the primary intended mechanism.
Selected difficult locations
The non-thermal mechanism is one reason IRE is studied around some vessels, ducts and other structures where thermal injury can be a concern. Difficult anatomy does not automatically make a tumor suitable.
Local is not systemic
Ablating one target does not treat microscopic or metastatic disease elsewhere. Surgery, systemic therapy and radiation remain separate treatment decisions.
Evidence by Indication: Do Not Treat “NanoKnife for Cancer” as One Claim
Evidence has to be read by cancer type, disease setting and treatment goal. Results from one organ should not be transferred automatically to another.
| Clinical question | Evidence signal | How ParkMega interprets it | Status |
|---|---|---|---|
| Locally advanced pancreatic cancer | Substantial research base; mixed comparative evidence | Potential selected-use question after staging, systemic-treatment review and anatomy assessment | Selective |
| Selected hepatic malignancies | IRE literature exists; direct comparison with RFA does not establish general superiority | Indication and anatomy matter more than the technology label | Indication-specific |
| Prostate focal therapy | Systematic-review literature exists | Requires disease-risk and focal-therapy review; not a generic travel indication | Research base |
| Other solid tumors | Varies substantially by organ and setting | Owning an IRE system is not evidence that IRE is appropriate for every tumor | Verify |
Evidence rule: “This hospital performs NanoKnife” and “NanoKnife improves outcomes for this patient” are different claims. ParkMega keeps mechanism, independent evidence, provider capability and case-specific eligibility separate.
NanoKnife for Pancreatic Cancer: The Most Important Decision Layer
Pancreatic cancer is one of the indications most closely associated with IRE — and one where marketing language can easily outrun the evidence.
The modified-Delphi consensus describes pancreatic IRE mainly in selected stage III disease and inoperable recurrent disease after prior local treatment, with multidisciplinary work-up and patient-selection requirements.
In the CROSSFIRE randomized phase-II study after FOLFIRINOX, IRE did not establish an overall-survival advantage over stereotactic ablative radiotherapy.
A useful proposal should explain stage, resectability, prior systemic therapy, anatomy, treatment goal and why IRE is being chosen over available alternatives.
Stage III does not mean automatic eligibility. Tumor size and geometry, vessel involvement, performance status, cardiac history, ascites, previous treatment and metastatic disease can change whether IRE is technically or medically appropriate.
Patient Selection and Contraindications
Questions that make IRE worth evaluating
- Is the disease localized enough for a local procedure to matter?
- Is surgery feasible, and if not, why not?
- Does tumor anatomy make the choice of ablation relevant?
- What systemic therapy has already been given?
- What is the defined treatment goal?
Factors that can change or stop the plan
- Cardiac rhythm problems and implanted electrical devices
- Severe cardiac disease or major comorbidity
- Ascites and poor performance status
- Tumor size, geometry and critical structures
- Metastatic disease where local treatment does not address the main problem
This is not a self-screening checklist. Individual eligibility requires review of pathology, staging and imaging by the treating clinical team.
IRE vs RFA, Microwave, Cryoablation and SABR
The useful comparison is not which technology sounds newer. It is which local treatment has the best rationale for the tumor, anatomy and treatment goal.
| Method | Main mechanism | Potential role | Important limitation |
|---|---|---|---|
| IRE / NanoKnife | Electrical, non-thermal | Selected local tumors where anatomy may make non-thermal ablation relevant | Evidence is indication-specific; invasive probe placement is required |
| Microwave ablation | Thermal | Established local ablation in selected liver, lung and other settings | Thermal injury and anatomy around critical structures matter |
| Radiofrequency ablation | Thermal | Long clinical history for selected local tumors | Heat-sink and location can affect treatment |
| Cryoablation | Freeze-thaw | Selected lung, liver, kidney, bone and other local-treatment settings | Different organ-specific evidence and complication profile |
| SABR / SBRT | Focused radiation | Non-surgical local treatment in selected cancers | Dose constraints, anatomy and prior radiation matter |
No automatic winner. Comparative evidence should not be rewritten as “NanoKnife is better.” For pancreatic cancer, randomized evidence does not establish general superiority of IRE over SABR.
China Provider Map: Capability Is Not the Same as Case Fit
Fuda Cancer Hospital
FUDA has a documented clinical and research history around IRE, including pancreatic-cancer research. Completed studies prove historical research activity; they do not prove current eligibility or comparative superiority.
Modern Cancer Hospital Guangzhou
Modern publishes NanoKnife among its minimally invasive technologies. Exact indication, physician, device configuration, international access and case acceptance still require verification.
Disease-specific cancer centers
An IRE proposal should be compared with disease-specific surgery, radiation and systemic-treatment options at major oncology centers when relevant.
How Much Does NanoKnife Cost in China?
ParkMega has not verified one authoritative China-wide NanoKnife price that can responsibly be presented as the cost for every patient.
IRE system + probes
Device configuration, disposable probes, imaging guidance and procedural complexity can affect the estimate.
Anesthesia + stay
Anesthesia, monitoring, room category and expected inpatient stay should be itemized.
Other treatment
Chemotherapy, targeted therapy, immunotherapy, radiation or additional procedures are separate decisions and costs.
Complications + extra days
Ask how additional procedures, ICU care or an extended stay would be billed if required.
Request a written itemized estimate after record review. An online “NanoKnife package price” without stage, imaging and a named treatment plan is not a reliable individual estimate.
See Cancer Treatment Cost in China and FUDA Cancer Hospital Cost.
What to Send for an IRE / NanoKnife Review
Minimum clinical packet
- Pathology report and exact diagnosis
- Current stage and metastatic sites
- Recent contrast CT / MRI / PET-CT as relevant
- DICOM imaging when available
- Previous surgery, radiation and systemic therapy
- Relevant biomarkers and molecular results
Questions the center should answer
- Exact tumor dimensions and relation to vessels / ducts
- Why surgery is not feasible or not preferred
- Why IRE instead of SABR, RFA, microwave or cryo
- Cardiac history and implanted electrical devices
- Performance status, ascites and organ function
- Defined treatment goal and systemic-treatment sequence
How ParkMega Handles a NanoKnife / IRE Case
Classify the disease
Diagnosis, histology, stage, imaging, biomarkers and previous treatment define the actual problem.
Test the IRE question
Separate evidence for the indication from the provider’s technology claim.
Compare alternatives
Verify provider access while comparing surgery, radiation, thermal ablation or systemic therapy when appropriate.
Have a NanoKnife proposal already?
Send the diagnosis, imaging summary and proposal. The goal is a case-specific evidence and provider check — not another generic technology pitch.
Questions to Ask Before Accepting a NanoKnife Proposal
Why IRE for this exact case?
Ask what disease or anatomy feature makes IRE preferable to surgery, radiation, thermal ablation, systemic therapy or observation.
Who will perform it?
Confirm the responsible physician, department, hospital campus and current procedural team.
Which IRE system and protocol?
Ask for the exact system, probe configuration, imaging guidance and evidence supporting the planned approach.
What are the patient-specific risks?
Ask about bowel, vascular, ductal, cardiac, anesthesia and other risks based on the actual scans and comorbidities.
What happens before and after IRE?
Clarify systemic treatment, radiation and follow-up imaging when relevant.
What is included?
Request procedure, anesthesia, imaging, probes, medicines, room, expected stay, follow-up and major exclusions.
Related China Cancer Guides
Frequently Asked Questions
Direct answers about NanoKnife / IRE evidence, pancreatic cancer, hospitals, eligibility and cost in China.
What is NanoKnife / IRE?
NanoKnife is a commonly used trade name associated with irreversible electroporation, or IRE. IRE is a non-thermal local-ablation technique using short high-voltage electrical pulses delivered through probes.
Is NanoKnife available in China?
Chinese providers including FUDA and Modern Cancer Hospital publish IRE or NanoKnife capability. Current physician availability, exact device configuration, indication and international-patient access should still be confirmed.
Is NanoKnife proven for pancreatic cancer?
Pancreatic IRE has a substantial research base, but evidence remains mixed. Expert consensus describes selected use, while randomized comparative evidence does not justify presenting IRE as a routinely superior replacement for standard pancreatic-cancer care.
Who may be considered for pancreatic IRE?
Expert consensus focuses on selected stage III pancreatic cancer and some inoperable recurrent disease after prior local treatment, but selection also depends on pathology, staging, anatomy, tumor size, performance status, cardiac factors, previous treatment and multidisciplinary review.
Does NanoKnife replace chemotherapy?
No. IRE is a local treatment. Systemic therapy addresses disease beyond one local target and may remain central to the treatment plan.
Is IRE better than microwave or radiofrequency ablation?
Not universally. Each technique has different mechanisms, anatomical constraints, risks and indication-specific evidence.
Is NanoKnife better than SABR for pancreatic cancer?
Current randomized comparative evidence does not establish general superiority of IRE over stereotactic ablative radiotherapy.
Which hospitals in China offer NanoKnife?
FUDA has a documented IRE research footprint and Modern Cancer Hospital Guangzhou publishes NanoKnife capability. Current indication, doctor availability and case acceptance should be verified for each patient.
How much does NanoKnife cost in China?
There is no single verified China-wide price that applies to every patient. Request an itemized estimate after record review.
What records should I send for an IRE review?
Usually pathology, current stage, recent contrast CT or MRI, DICOM files when available, metastatic sites, previous treatment, relevant biomarkers, current medicines, major comorbidities and cardiac history.
Sources and Evidence
- Pancreatic IRE expert consensus (2024). Modified-Delphi consensus on patient selection, contraindications, technique and follow-up. PMC11236456.
- CROSSFIRE randomized phase-II trial. IRE versus stereotactic ablative radiotherapy after FOLFIRINOX for locally advanced pancreatic cancer. PMC11148833.
- IRE versus RFA for hepatic malignancies (2026). Direct-comparison systematic review and meta-analysis. PMID 42504355.
- FUDA NanoKnife / IRE evidence review. ParkMega FUDA NanoKnife guide.
- ClinicalTrials.gov NCT02981719. Completed FUDA-sponsored study of gemcitabine plus IRE versus IRE for locally advanced pancreatic cancer; used as historical research evidence, not current recruitment proof.
Freshness note: device models, doctor schedules, treatment availability, prices and international-patient access can change. Verify the actual hospital proposal before travel or payment.
Medical note: this page explains evidence and access. It does not diagnose cancer, recommend IRE for a specific patient, guarantee eligibility or replace multidisciplinary oncology advice.
Check the Case Before Choosing the Technology
Send pathology, stage, recent imaging and previous treatment. The useful output is to determine whether IRE is a medically relevant question, which evidence applies, which China providers can review the case and what must be confirmed before travel.
✓ No cure claim✓ No automatic eligibility✓ Provider capability separated from efficacy✓ Cost requested after treatment fit